title: Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Michelina
authors.initials: M
authors.lastname: Santopietro
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Loglisci
authors.forename: Fabio
authors.initials: F
authors.lastname: Stagno
authors.forename: Laura
authors.initials: L
authors.lastname: Cannella
authors.forename: Ida
authors.initials: I
authors.lastname: Carmosino
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D014859:Warfarin; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases